Agomab outlines design of phase 2b NOV‑ERA study in fibrostenosing Crohn’s disease
24th June 2026 Uncategorised 0
FDA alignment secured as company prepares to begin dosing in 2026

More: Agomab outlines design of phase 2b NOV‑ERA study in fibrostenosing Crohn’s disease
Source: News
